Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.

Bonello L, Camoin-Jau L, Mancini J, Bessereau J, Grosdidier C, Alessi MC, Ostorero M, Dignat-George F, Paganelli F.

Thromb Res. 2012 Jul;130(1):70-4. doi: 10.1016/j.thromres.2011.12.038. Epub 2012 Jan 27.

PMID:
22285300
2.

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.

Bonello L, Armero S, Ait Mokhtar O, Mancini J, Aldebert P, Saut N, Bonello N, Barragan P, Arques S, Giacomoni MP, Bonello-Burignat C, Bartholomei MN, Dignat-George F, Camoin-Jau L, Paganelli F.

J Am Coll Cardiol. 2010 Nov 9;56(20):1630-6. doi: 10.1016/j.jacc.2010.07.004. Epub 2010 Aug 12.

3.

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.

Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C.

Thromb Haemost. 2013 Dec;110(6):1223-31. doi: 10.1160/TH13-03-0263. Epub 2013 Sep 5.

PMID:
24009042
4.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators.

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
5.

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Lévy N, Maillard L, Barragan P, Dignat-George F, Camoin-Jau L, Bonello L.

Am J Cardiol. 2009 Dec 1;104(11):1511-5. doi: 10.1016/j.amjcard.2009.07.015.

PMID:
19932784
6.

Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.

Bonello L, Bonello-Palot N, Armero S, Bonello C, Mokhtar OA, Arques S, Dignat-George F, Camoin-Jau L, Paganelli F.

Thromb Res. 2010 Apr;125(4):e167-70. doi: 10.1016/j.thromres.2009.10.014. Epub 2009 Nov 14.

PMID:
19914687
7.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
8.

Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.

Rideg O, Komócsi A, Magyarlaki T, Tokés-Füzesi M, Miseta A, Kovács GL, Aradi D.

Pharmacogenomics. 2011 Sep;12(9):1269-80. doi: 10.2217/pgs.11.73. Epub 2011 Aug 1.

PMID:
21806387
9.

Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance.

Wang XD, Zhang DF, Liu XB, Lai Y, Qi WG, Luo Y, Hu B, Yao YA.

Eur J Intern Med. 2012 Jan;23(1):48-53. doi: 10.1016/j.ejim.2011.07.016. Epub 2011 Sep 3.

PMID:
22153531
10.

Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.

Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K.

J Cardiol. 2013 Sep;62(3):158-64. doi: 10.1016/j.jjcc.2013.03.006. Epub 2013 Jul 22.

11.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

12.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
13.

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.

Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML.

JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008.

15.
16.

Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.

González A, Moniche F, Cayuela A, García-Lozano JR, Torrecillas F, Escudero-Martínez I, Gonzalez-Marcos JR, Mayol A, Montaner J.

Eur J Vasc Endovasc Surg. 2016 Feb;51(2):175-86. doi: 10.1016/j.ejvs.2015.09.020. Epub 2015 Oct 31.

17.
18.

Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness.

Latkovskis G, Urtane I, Knipse A, Peculis R, Cakstina I, Klovins J, Erglis A.

Medicina (Kaunas). 2014;50(1):19-27. doi: 10.1016/j.medici.2014.05.004. Epub 2014 Jun 6.

19.

Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism.

Bonello L, Palot-Bonello N, Armero S, Camoin-Jau L, Paganelli F.

Int J Cardiol. 2010 Nov 5;145(1):165-6. doi: 10.1016/j.ijcard.2009.07.033. Epub 2009 Aug 26.

PMID:
19712984
20.

Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.

Bonello L, Laine M, Camoin-Jau L, Noirot F, Guieu R, Dignat-George F, Paganelli F, Frere C.

Thromb Haemost. 2015 Oct;114(4):702-7. doi: 10.1160/TH15-02-0149. Epub 2015 Aug 27.

PMID:
26311415

Supplemental Content

Support Center